The study aimed to create and assess mucoadhesive nanoemulsion-based drug delivery systems (MNEs) for the effective delivery of antimigraine agents into the central nervous system (CNS). The research investigated three categories of drugs: triptans, beta-blockers, and ACE inhibitors, focusing on their potential to improve therapeutic outcomes for migraine treatment. Drug Selected were Triptans: Sumatriptan, Zolmitriptan, Almotriptan, Beta-Blockers: Propranolol, Timolol, Nadolol, ACE Inhibitors : Captopril, Enalapril, Lisinopril Nanoemulsion FormulationMNEs were prepared using standard nanoemulsion techniques, incorporating mucoadhesive polymers to enhance retention in the nasal cavity.The formulations were evaluated for drug release profiles, mucoadhesive strength, and stability.Results Triptans• Sumatriptan: MNEs showed acumulative drug release of 83.43% after 8 hours.• Zolmitriptan:MNEs exhibited acumulative drug release of 83.63% after 8 hours.• Almotriptan: Demonstrated the highest cumulative drug releaseat89.04% after 8 hours.Overall, MNEs significantly improved drug release for all triptans compared to traditional NEs and plain drug solutions (PDS).